Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1999 Feb;54(2):108–114. doi: 10.1136/thx.54.2.108

Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma

A Jatakanon 1, S Kharitonov 1, S Lim 1, P Barnes 1
PMCID: PMC1745406  PMID: 10325913

Abstract

BACKGROUND—It is desirable to prescribe the minimal effective dose of inhaled steroids to control asthma. To ensure that inflammation is suppressed whilst using the lowest possible dose, a sensitive and specific method for assessing airway inflammation is needed.
METHODS—The usefulness of exhaled nitric oxide (NO), sputum eosinophils, and methacholine airway responsiveness (PC20) for monitoring airway inflammatory changes following four weeks of treatment with an inhaled corticosteroid (budesonide via Turbohaler) were compared. Mild stable steroid naive asthmatic subjects were randomised into two double blind, placebo controlled studies. The first was a parallel group study involving three groups receiving either 100 µg/day budesonide (n = 8), 400 µg/day budesonide (n = 7), or a matched placebo (n = 6). The second was a crossover study involving 10 subjects randomised to receive 1600 µg budesonide or placebo. The groups were matched with respect to age, PC20, baseline FEV1 (% predicted), exhaled NO, and sputum eosinophilia.
RESULTS—There were significant improvements in FEV1 following 400 µg and 1600 µg budesonide (11.3% and 6.5%, respectively, p<0.05). This was accompanied by significant reductions in eosinophil numbers in induced sputum (0.7 and 0.9 fold, p<0.05). However, levels of exhaled NO were reduced following each budesonide dose while PC20 was improved only with 1600 µg budesonide. These results suggest that exhaled NO and PC20 may not reflect the control of airway inflammation as accurately as the number of eosinophils in sputum. There were dose dependent changes in exhaled NO, sputum eosinophils, and PC20 to inhaled budesonide but a plateau response of exhaled NO was found at a dose of 400 µg daily.
CONCLUSION—Monitoring the number of eosinophils in induced sputum may be the most accurate guide to establish the minimum dose of inhaled steroids needed to control inflammation. This, however, requires further studies involving a larger number of patients.



Full Text

The Full Text of this article is available as a PDF (140.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baigelman W., Chodosh S., Pizzuto D., Cupples L. A. Sputum and blood eosinophils during corticosteroid treatment of acute exacerbations of asthma. Am J Med. 1983 Dec;75(6):929–936. doi: 10.1016/0002-9343(83)90871-9. [DOI] [PubMed] [Google Scholar]
  2. Barnes P. J. New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma. J Allergy Clin Immunol. 1989 Jun;83(6):1013–1026. doi: 10.1016/0091-6749(89)90441-7. [DOI] [PubMed] [Google Scholar]
  3. Booth H., Richmond I., Ward C., Gardiner P. V., Harkawat R., Walters E. H. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. Am J Respir Crit Care Med. 1995 Jul;152(1):45–52. doi: 10.1164/ajrccm.152.1.7599861. [DOI] [PubMed] [Google Scholar]
  4. Boulet L. P., Laviolette M., Turcotte H., Cartier A., Dugas M., Malo J. L., Boutet M. Bronchial subepithelial fibrosis correlates with airway responsiveness to methacholine. Chest. 1997 Jul;112(1):45–52. doi: 10.1378/chest.112.1.45. [DOI] [PubMed] [Google Scholar]
  5. Busse W. W., Chervinsky P., Condemi J., Lumry W. R., Petty T. L., Rennard S., Townley R. G. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol. 1998 Apr;101(4 Pt 1):457–463. doi: 10.1016/S0091-6749(98)70353-7. [DOI] [PubMed] [Google Scholar]
  6. Chai H., Farr R. S., Froehlich L. A., Mathison D. A., McLean J. A., Rosenthal R. R., Sheffer A. L., Spector S. L., Townley R. G. Standardization of bronchial inhalation challenge procedures. J Allergy Clin Immunol. 1975 Oct;56(4):323–327. doi: 10.1016/0091-6749(75)90107-4. [DOI] [PubMed] [Google Scholar]
  7. Claman D. M., Boushey H. A., Liu J., Wong H., Fahy J. V. Analysis of induced sputum to examine the effects of prednisone on airway inflammation in asthmatic subjects. J Allergy Clin Immunol. 1994 Nov;94(5):861–869. doi: 10.1016/0091-6749(94)90154-6. [DOI] [PubMed] [Google Scholar]
  8. Corrigan C. J., Hamid Q., North J., Barkans J., Moqbel R., Durham S., Gemou-Engesaeth V., Kay A. B. Peripheral blood CD4 but not CD8 t-lymphocytes in patients with exacerbation of asthma transcribe and translate messenger RNA encoding cytokines which prolong eosinophil survival in the context of a Th2-type pattern: effect of glucocorticoid therapy. Am J Respir Cell Mol Biol. 1995 May;12(5):567–578. doi: 10.1165/ajrcmb.12.5.7742019. [DOI] [PubMed] [Google Scholar]
  9. Gershman N. H., Wong H. H., Liu J. T., Mahlmeister M. J., Fahy J. V. Comparison of two methods of collecting induced sputum in asthmatic subjects. Eur Respir J. 1996 Dec;9(12):2448–2453. doi: 10.1183/09031936.96.09122448. [DOI] [PubMed] [Google Scholar]
  10. Gibson P. G., Girgis-Gabardo A., Morris M. M., Mattoli S., Kay J. M., Dolovich J., Denburg J., Hargreave F. E. Cellular characteristics of sputum from patients with asthma and chronic bronchitis. Thorax. 1989 Sep;44(9):693–699. doi: 10.1136/thx.44.9.693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gibson P. G., Wong B. J., Hepperle M. J., Kline P. A., Girgis-Gabardo A., Guyatt G., Dolovich J., Denburg J. A., Ramsdale E. H., Hargreave F. E. A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid. Clin Exp Allergy. 1992 May;22(5):525–532. doi: 10.1111/j.1365-2222.1992.tb00161.x. [DOI] [PubMed] [Google Scholar]
  12. Haahtela T., Järvinen M., Kava T., Kiviranta K., Koskinen S., Lehtonen K., Nikander K., Persson T., Selroos O., Sovijärvi A. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med. 1994 Sep 15;331(11):700–705. doi: 10.1056/NEJM199409153311103. [DOI] [PubMed] [Google Scholar]
  13. Hallsworth M. P., Litchfield T. M., Lee T. H. Glucocorticoids inhibit granulocyte-macrophage colony-stimulating factor-1 and interleukin-5 enhanced in vitro survival of human eosinophils. Immunology. 1992 Feb;75(2):382–385. [PMC free article] [PubMed] [Google Scholar]
  14. Jatakanon A., Lim S., Kharitonov S. A., Chung K. F., Barnes P. J. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax. 1998 Feb;53(2):91–95. doi: 10.1136/thx.53.2.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jones A. H., Langdon C. G., Lee P. S., Lingham S. A., Nankani J. P., Follows R. M., Tollemar U., Richardson P. D. Pulmicort Turbohaler once daily as initial prophylactic therapy for asthma. Respir Med. 1994 Apr;88(4):293–299. doi: 10.1016/0954-6111(94)90059-0. [DOI] [PubMed] [Google Scholar]
  16. Juniper E. F., Kline P. A., Vanzieleghem M. A., Ramsdale E. H., O'Byrne P. M., Hargreave F. E. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis. 1990 Oct;142(4):832–836. doi: 10.1164/ajrccm/142.4.832. [DOI] [PubMed] [Google Scholar]
  17. Juniper E. F., Kline P. A., Vanzieleghem M. A., Ramsdale E. H., O'Byrne P. M., Hargreave F. E. Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics. Eur Respir J. 1990 Nov;3(10):1122–1127. [PubMed] [Google Scholar]
  18. Keatings V. M., Jatakanon A., Worsdell Y. M., Barnes P. J. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med. 1997 Feb;155(2):542–548. doi: 10.1164/ajrccm.155.2.9032192. [DOI] [PubMed] [Google Scholar]
  19. Kerstjens H. A., Brand P. L., Hughes M. D., Robinson N. J., Postma D. S., Sluiter H. J., Bleecker E. R., Dekhuijzen P. N., de Jong P. M., Mengelers H. J. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group. N Engl J Med. 1992 Nov 12;327(20):1413–1419. doi: 10.1056/NEJM199211123272003. [DOI] [PubMed] [Google Scholar]
  20. Kharitonov S. A., Chung K. F., Evans D., O'Connor B. J., Barnes P. J. Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract. Am J Respir Crit Care Med. 1996 Jun;153(6 Pt 1):1773–1780. doi: 10.1164/ajrccm.153.6.8665033. [DOI] [PubMed] [Google Scholar]
  21. Kharitonov S. A., Yates D. H., Barnes P. J. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med. 1996 Jan;153(1):454–457. doi: 10.1164/ajrccm.153.1.8542158. [DOI] [PubMed] [Google Scholar]
  22. Kharitonov S. A., Yates D., Robbins R. A., Logan-Sinclair R., Shinebourne E. A., Barnes P. J. Increased nitric oxide in exhaled air of asthmatic patients. Lancet. 1994 Jan 15;343(8890):133–135. doi: 10.1016/s0140-6736(94)90931-8. [DOI] [PubMed] [Google Scholar]
  23. Lamas A. M., Leon O. G., Schleimer R. P. Glucocorticoids inhibit eosinophil responses to granulocyte-macrophage colony-stimulating factor. J Immunol. 1991 Jul 1;147(1):254–259. [PubMed] [Google Scholar]
  24. Pizzichini E., Pizzichini M. M., Efthimiadis A., Dolovich J., Hargreave F. E. Measuring airway inflammation in asthma: eosinophils and eosinophilic cationic protein in induced sputum compared with peripheral blood. J Allergy Clin Immunol. 1997 Apr;99(4):539–544. doi: 10.1016/s0091-6749(97)70082-4. [DOI] [PubMed] [Google Scholar]
  25. Pizzichini E., Pizzichini M. M., Efthimiadis A., Evans S., Morris M. M., Squillace D., Gleich G. J., Dolovich J., Hargreave F. E. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):308–317. doi: 10.1164/ajrccm.154.2.8756799. [DOI] [PubMed] [Google Scholar]
  26. Pizzichini M. M., Pizzichini E., Clelland L., Efthimiadis A., Mahony J., Dolovich J., Hargreave F. E. Sputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatment. Am J Respir Crit Care Med. 1997 May;155(5):1501–1508. doi: 10.1164/ajrccm.155.5.9154849. [DOI] [PubMed] [Google Scholar]
  27. Sont J. K., Han J., van Krieken J. M., Evertse C. E., Hooijer R., Willems L. N., Sterk P. J. Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids. Thorax. 1996 May;51(5):496–502. doi: 10.1136/thx.51.5.496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Vathenen A. S., Knox A. J., Wisniewski A., Tattersfield A. E. Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. Am Rev Respir Dis. 1991 Jun;143(6):1317–1321. doi: 10.1164/ajrccm/143.6.1317. [DOI] [PubMed] [Google Scholar]
  29. Wallen N., Kita H., Weiler D., Gleich G. J. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol. 1991 Nov 15;147(10):3490–3495. [PubMed] [Google Scholar]
  30. in 't Veen J. C., de Gouw H. W., Smits H. H., Sont J. K., Hiemstra P. S., Sterk P. J., Bel E. H. Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthma. Eur Respir J. 1996 Dec;9(12):2441–2447. doi: 10.1183/09031936.96.09122441. [DOI] [PubMed] [Google Scholar]
  31. van Essen-Zandvliet E. E., Hughes M. D., Waalkens H. J., Duiverman E. J., Pocock S. J., Kerrebijn K. F. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group. Am Rev Respir Dis. 1992 Sep;146(3):547–554. doi: 10.1164/ajrccm/146.3.547. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES